-

Agenus to Provide Second Quarter 2023 Financial Report and Corporate Update

Company Announces Participation in BTIG Virtual Biotechnology Conference

LEXINGTON, Mass.--(BUSINESS WIRE)--Immuno-oncology leader, Agenus (Nasdaq: AGEN), today announced the Company will release its second quarter 2023 financial results via press release before the market opens on Tuesday, August 8, 2023.

In addition, Dr. Garo Armen, Chairman and CEO of Agenus, will participate in the following upcoming investor conferences:

  • BTIG Virtual Biotechnology Conference 2023 – Fireside chat presentation will be held virtually on Monday, August 7th, 2023 at 3:00 PM ET.

A replay of the fireside chat from the BTIG conference can be accessed on the company’s website at https://investor.agenusbio.com/events-and-presentations following the event.

About Agenus

Agenus is a leading immuno-oncology company targeting cancer and infectious diseases with a comprehensive pipeline of immunological agents. The Company’s mission is to expand patient populations benefiting from cancer immunotherapy through combination approaches, using a broad repertoire of antibody therapeutics, adoptive cell therapies (through MiNK Therapeutics), and adjuvants (through SaponiQx). Agenus is headquartered in Lexington, MA. For more information, visit www.agenusbio.com or follow us on LinkedIn and Twitter @agenus_bio.

Contacts

Investor Contact
Zack Armen
917-362-1370
investors@agenusbio.com

Media Contact
781-674-4784
communications@agenusbio.com

Industry:

Agenus

NASDAQ:AGEN
Release Versions
English

Contacts

Investor Contact
Zack Armen
917-362-1370
investors@agenusbio.com

Media Contact
781-674-4784
communications@agenusbio.com

More News From Agenus

Agenus Announces Oversubscribed Private Placement of Up to $340 Million to Advance Registrational ROBBIN Trial of Neoadjuvant BOT+BAL in MSS Colon Cancer

LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that it has entered into a securities purchase agreement for a private placement of approximately $85 million in upfront gross proceeds, before the deduction of private placement expenses, and up to an additional $255 million upon the full exercise of purchase warrants. The financing was led by Commodore Capital, with participation from RA Capital Management, TCGX, Invus, and L...

Agenus Reports Landmark BOT+BAL Data Showing 33% Three-Year Overall Survival in Refractory MSS Metastatic Colorectal Cancer Without Active Liver Metastases at ESMO GI 2026

LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced three-year landmark Phase 1b data from the fully enrolled C-800-01 cohort evaluating botensilimab (BOT), an Fc-enhanced multifunctional anti–CTLA-4 antibody, plus balstilimab (BAL), an anti–PD-1 antibody, in patients with refractory microsatellite-stable (MSS) metastatic colorectal cancer (mCRC) without active liver metastases. The data were presented at the European Society fo...

Agenus Announces Three-Year Survival Data from Phase 1b BOT+BAL Study in MSS Metastatic Colorectal Cancer to be Presented at ESMO GI 2026

LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that three-year survival data from the Phase 1b C-800-01 study of botensilimab (BOT), an Fc-enhanced multifunctional anti–CTLA-4 antibody, plus balstilimab (BAL), an anti–PD-1 antibody, in patients with microsatellite stable (MSS) metastatic colorectal cancer (mCRC) without active liver metastases will be presented at the European Society for Medical Oncology Gastrointestinal C...
Back to Newsroom